News
INMB
1.510
-4.43%
-0.070
Inmune Bio Advances Immunotherapy Pipeline with Phase 2 Completion
TipRanks · 1d ago
Weekly Report: what happened at INMB last week (1103-1107)?
Weekly Report · 1d ago
INmune Bio (INMB) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
NASDAQ · 5d ago
Maxim Group Sticks to Their Buy Rating for Inmune Bio (INMB)
TipRanks · 11/03 21:05
Inmune Bio (INMB) Gets a Hold from BTIG
TipRanks · 11/03 16:58
Weekly Report: what happened at INMB last week (1027-1031)?
Weekly Report · 11/03 09:53
Inmune Bio’s Earnings Call Highlights Progress and Challenges
TipRanks · 11/01 00:40
Inmune Bio Reports Q3 2025 Financial Results
TipRanks · 10/31 04:43
Inmune Bio outlines 2026 regulatory milestones and cash runway through Q4 2026
Seeking Alpha · 10/31 03:17
INmune Bio reports Q3 EPS (24c), consensus (32c)
TipRanks · 10/30 20:46
INmune Bio Q3 net loss narrows to $6.5 mln, names new CEO
Reuters · 10/30 20:30
*INmune Bio Says Cory Ellspermann Has Been Appointed as CFO >INMB
Dow Jones · 10/30 20:30
*INmune Bio Says Kelly Ganjei Named as Chmn of the Bd >INMB
Dow Jones · 10/30 20:30
*INmune Bio Says RJ Tesi Is Retiring as President, CEO >INMB
Dow Jones · 10/30 20:29
*INmune Bio Names David Moss President, CEO >INMB
Dow Jones · 10/30 20:29
*INmune Bio 3Q Loss $6.47M >INMB
Dow Jones · 10/30 20:28
INmune Bio GAAP EPS of -$0.24 beats by $0.09
Seeking Alpha · 10/30 20:17
INmune Bio Q3 Adj. EPS $(0.24) Beats $(0.33) Estimate
Benzinga · 10/30 20:14
Press Release: INmune Bio Inc. Announces Third Quarter 2025 Results and Provides Business Update
Dow Jones · 10/30 20:05
*INmune Bio 3Q Loss/Shr 24c >INMB
Dow Jones · 10/30 20:05
More
Webull provides a variety of real-time INMB stock news. You can receive the latest news about Inmune Bio Inc through multiple platforms. This information may help you make smarter investment decisions.
About INMB
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The Company has three product platforms. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune, developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that has completed a trial in recessive dystrophic epidermolysis bullosa.